Cargando…

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas

BACKGROUND: Except for gene fusions, FGFR2 genetic alterations in intrahepatic cholangiocarcinomas (ICCs) have received limited attention, leaving patients harboring activating FGFR2 gene mutations with inadequate access to targeted therapies. EXPERIMENTAL DESIGN: We sought to survey FGFR2 genetic a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pu, Xiaohong, Qi, Liang, Yan, Jia Wu, Ai, Zihe, Wu, Ping, Yang, Fei, Fu, Yao, Li, Xing, Zhang, Min, Sun, Beicheng, Yue, Shen, Chen, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644541/ https://www.ncbi.nlm.nih.gov/pubmed/37964396 http://dx.doi.org/10.1186/s13578-023-01156-7

Ejemplares similares

Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas
por: Pu, Xiaohong, et al.
Publicado: (2021)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients
por: Zhang, Lei, et al.
Publicado: (2023)

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
por: Abou-Alfa, Ghassan K., et al.
Publicado: (2022)

The role of FGFR inhibitors in the treatment of intrahepatic cholangiocarcinoma—unveiling the future challenges in drug therapy
por: Nishida, Naoshi
Publicado: (2023)

Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma
por: Zhao, Linghao, et al.
Publicado: (2022)

FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib
por: Ying, Xihui, et al.
Publicado: (2019)

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
por: Mazzaferro, Vincenzo, et al.
Publicado: (2018)

Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
por: Salati, Massimiliano, et al.
Publicado: (2021)

Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
por: Peng, Min, et al.
Publicado: (2023)

Sprouty2 suppresses progression and correlates to favourable prognosis of intrahepatic cholangiocarcinoma via antagonizing FGFR2 signalling
por: Xu, Yun‐Fei, et al.
Publicado: (2018)

Alterations of gut mycobiota profiles in intrahepatic cholangiocarcinoma
por: Zhang, Lilong, et al.
Publicado: (2023)

Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
por: Borad, Mitesh J., et al.
Publicado: (2014)

The role of microRNAs in intrahepatic cholangiocarcinoma
por: Li, Zheng, et al.
Publicado: (2016)

Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2017)

Erratum to: Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies
por: Lidsky, Michael E., et al.
Publicado: (2022)

A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma
por: Chu, Zhenzhen, et al.
Publicado: (2023)

Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma
por: Dalmasso, Cyril, et al.
Publicado: (2015)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
por: Ishido, Shun, et al.
Publicado: (2023)

Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
por: Peng, Jianbo, et al.
Publicado: (2023)

High endothelial venule is a prognostic immune‐related biomarker in patients with resected intrahepatic cholangiocarcinoma
por: Zhou, Yan, et al.
Publicado: (2023)

Intrahepatic Sarcomatoid Cholangiocarcinoma
por: Malhotra, Shalini, et al.
Publicado: (2010)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Management of Intrahepatic Cholangiocarcinoma
por: Kodali, Sudha, et al.
Publicado: (2021)

Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma
por: Chen, Xing, et al.
Publicado: (2022)

First proficiency testing for NGS‐based and combined NGS‐ and FISH‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma
por: Neumann, Olaf, et al.
Publicado: (2023)

Case Report: Primary lymphoepithelioma-like intrahepatic cholangiocarcinoma
por: Liu, Fei, et al.
Publicado: (2023)

Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
por: Wang, Jing, et al.
Publicado: (2020)

Prognostic Significance of Capn4 Overexpression in Intrahepatic Cholangiocarcinoma
por: Zhang, Chi, et al.
Publicado: (2013)

Influence of marital status on the survival of adults with extrahepatic/intrahepatic cholangiocarcinoma
por: Chen, Zhiqiang, et al.
Publicado: (2017)

Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma
por: Marcus, Rebecca, et al.
Publicado: (2021)

Diabetes and PKM2 affect prognosis in patients with intrahepatic cholangiocarcinoma
por: Fu, Kui, et al.
Publicado: (2020)

Two Varieties of Intrahepatic Cholangiocarcinoma
por: Nagorney, David M.
Publicado: (1994)

Intrahepatic Cholangiocarcinoma with Sarcomatous Changes
por: Inoue, Yoshiyuki, et al.
Publicado: (2012)

Serum Markers of Intrahepatic Cholangiocarcinoma
por: Malaguarnera, Giulia, et al.
Publicado: (2013)

Intrahepatic cholangiocarcinoma: current perspectives
por: Buettner, Stefan, et al.
Publicado: (2017)

Intratumoral heterogeneity of intrahepatic cholangiocarcinoma
por: Walter, Dirk, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p2ufl0drvtj87fl9ssg8gtsi5v